Connect with us


Boehringer overtakes Bayer as Germany’s top drugmaker thanks to success of Jardiance, ET HealthWorld reports



Boehringer replaces Bayer as Germany's largest drugmaker on Jardiance gains, ET HealthWorld

Boehringer Ingelheim has surpassed Bayer to become Germany’s largest drugmaker, with a reported increase in pharmaceutical sales of 10.3% to 20.8 billion euros in 2023. Bayer, on the other hand, experienced a 6% decline in pharmaceutical sales to 18.1 billion euros in the same year. Boehringer’s growth was primarily attributed to the success of diabetes drug Jardiance and lung drug Ofev, driving the overall group sales up by 9.7% to 25.6 billion euros.

The success of Boehringer’s Jardiance group of products, in partnership with Eli Lilly, resulted in a currency-adjusted surge of 31% to 7.4 billion euros in annual sales. Additionally, sales of the pulmonary fibrosis drug Ofev saw a currency-adjusted increase of 12.8% to 3.5 billion euros. Boehringer also announced a collaboration with Zealand Pharma to develop a weight loss drug, set to launch in 2027 or 2028, to compete with Lilly’s obesity drug Mounjaro.

Looking ahead to 2024, Boehringer expects a slight increase in group revenues, adjusted for currency fluctuations and one-off effects. The company’s focus on innovation and strategic partnerships has positioned it as a key player in the pharmaceutical industry. With a strong portfolio of successful drugs and promising collaborations, Boehringer Ingelheim continues to make strides in the healthcare sector.

In conclusion, Boehringer Ingelheim’s recent achievements in pharmaceutical sales highlight its growing presence in the market, outpacing competitors and solidifying its position as a leader in the industry.

Click to comment

You must be logged in to post a comment Login

Leave a Reply